Form 4: Rhythm Pharmaceuticals Executive Joseph Shulman Reports Stock Transactions

Chief Technical Officer Joseph Shulman of Rhythm Pharmaceuticals reports the acquisition and disposal of common stock and restricted stock units.

Summary

• Joseph Shulman, Chief Technical Officer of Rhythm Pharmaceuticals, filed a Form 4 detailing changes in beneficial ownership.
• On February 9, 2025, Shulman acquired 2,656 shares of common stock through the vesting of restricted stock units.
• On February 11, 2025, Shulman acquired 1,562 shares of common stock through the vesting of restricted stock units.
• Also on February 11, 2025, Shulman disposed of 791 shares at $57.51 and 3 shares at $57.54 to cover withholding taxes related to the vesting of restricted stock units.
• Following these transactions, Shulman directly owns 6,081 shares of Rhythm Pharmaceuticals common stock.

Sentiment

Score: 5

Explanation: This is a routine filing related to stock transactions by an executive. It doesn't inherently indicate positive or negative sentiment, but rather provides factual information.

Industry Context

Form 4 filings are a routine part of the US stock market, providing transparency into the transactions of company insiders. This filing indicates the executive's transactions in company stock, which can be of interest to investors.

Stakeholder Impact

• Shareholders may be interested in the trading activity of company insiders as it can provide insights into management's perspective on the company's value.

Key Dates

Keywords

Form 4, Beneficial Ownership, Rhythm Pharmaceuticals, RYTM, Joseph Shulman, Stock Transactions, Restricted Stock Units, Vesting, Withholding Taxes